← Database
Mitochondrial Uncoupler

BAM15

Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

A small-molecule mitochondrial protonophore (uncoupler) studied preclinically for obesity and metabolic disease; not a peptide and not approved for human use.

How it works

BAM15 is a small molecule (not a peptide) that acts as a mitochondrial "uncoupler." Mitochondria normally build up a proton gradient across their inner membrane and then harvest that gradient to make ATP, the cell's energy currency. An uncoupler lets protons leak back across the membrane without making ATP, so the energy is released as heat instead — effectively making the cell burn more fuel.

The interest in BAM15 is metabolic: by increasing energy expenditure, uncouplers can, in animal models, reduce body fat and improve markers of metabolic health without requiring reduced food intake. BAM15 was specifically pursued because it was reported to act on mitochondria while having a wider safety margin in preclinical studies than older, dangerous uncouplers such as DNP (2,4-dinitrophenol).

The evidence base is preclinical. BAM15's reported metabolic benefits come from cell and rodent studies; it is not an approved medicine and human clinical safety and efficacy are not established. Because uncoupling raises energy expenditure and heat production, the entire chemical class carries an inherent and potentially serious risk if dosing is excessive.

Mechanism · Detailed Analysis
Molecular targetBAM15 functions as a protonophore that uncouples oxidative phosphorylation at the mitochondrial inner membrane. It is reported to selectively dissipate the proton-motive force across the inner mitochondrial membrane without significantly depolarizing the plasma membrane, which is the proposed basis for a better safety margin than non-selective uncouplers.
Signaling & downstream effectsBy collapsing the proton gradient, BAM15 lowers the efficiency of ATP synthesis and increases electron transport chain activity and substrate oxidation, raising energy expenditure and generating heat (thermogenesis). Downstream, preclinical work reports reduced adiposity, improved insulin sensitivity, and shifts in fuel utilization, though these outcomes are model-dependent.
PharmacokineticsDetailed, validated human pharmacokinetic data are not established. Preclinical reports note that exposure and the relatively narrow practical window of uncoupler dosing are important considerations, but reliable human PK and dose-response information is lacking.
CaveatsMitochondrial uncoupling is intrinsically hazardous: excessive uncoupling can cause hyperthermia and energy crisis, the mechanism behind the toxicity of older agents like DNP. BAM15 is investigational, unapproved, and not characterized for human safety; its preclinical "wider margin" does not equal proven human safety.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.